122 related articles for article (PubMed ID: 11237071)
1. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker.
ten Berge RL; Oudejans JJ; Dukers DF; Meijer JW; Ossenkoppele GJ; Meijer CJ
Leukemia; 2001 Mar; 15(3):458-64. PubMed ID: 11237071
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma.
ten Berge RL; Dukers DF; Oudejans JJ; Pulford K; Ossenkoppele GJ; de Jong D; Miseré JF; Meijer CJ
Blood; 1999 Apr; 93(8):2688-96. PubMed ID: 10194449
[TBL] [Abstract][Full Text] [Related]
3. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease.
Oudejans JJ; Jiwa NM; Kummer JA; Ossenkoppele GJ; van Heerde P; Baars JW; Kluin PM; Kluin-Nelemans JC; van Diest PJ; Middeldorp JM; Meijer CJ
Blood; 1997 Feb; 89(4):1376-82. PubMed ID: 9028961
[TBL] [Abstract][Full Text] [Related]
4. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients.
Kagami Y; Suzuki R; Taji H; Yatabe Y; Takeuchi T; Maeda S; Kondo E; Kojima M; Motoori T; Mizoguchi Y; Okamoto M; Ohnishi K; Yamabe H; Seto M; Ogura M; Koshikawa T; Takahashi T; Kurita S; Morishima Y; Suchi T; Nakamura S
Am J Surg Pathol; 1999 Oct; 23(10):1184-200. PubMed ID: 10524519
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma.
Asano N; Suzuki R; Matsuo K; Kagami Y; Ishida F; Tamaru JI; Jin GS; Sato Y; Shimoyama Y; Yoshino T; Morishima Y; Nakamura S
Histopathology; 2007 May; 50(6):705-15. PubMed ID: 17493234
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules.
Foss HD; Anagnostopoulos I; Araujo I; Assaf C; Demel G; Kummer JA; Hummel M; Stein H
Blood; 1996 Nov; 88(10):4005-11. PubMed ID: 8916967
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.
Muris JJ; Meijer CJ; Cillessen SA; Vos W; Kummer JA; Bladergroen BA; Bogman MJ; MacKenzie MA; Jiwa NM; Siegenbeek van Heukelom LH; Ossenkoppele GJ; Oudejans JJ
Leukemia; 2004 Mar; 18(3):589-96. PubMed ID: 14712286
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin.
Krenacs L; Wellmann A; Sorbara L; Himmelmann AW; Bagdi E; Jaffe ES; Raffeld M
Blood; 1997 Feb; 89(3):980-9. PubMed ID: 9028330
[TBL] [Abstract][Full Text] [Related]
10. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.
ten Berge RL; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Oudejans JJ; Meijer JW; Willemze R; Hilgers J; Meijer CJ
J Clin Pathol; 2001 Dec; 54(12):933-9. PubMed ID: 11729213
[TBL] [Abstract][Full Text] [Related]
11. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
[TBL] [Abstract][Full Text] [Related]
12. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas.
Dukers DF; ten Berge RL; Oudejans JJ; Pulford K; Hayes D; Miseré JF; Ossenkoppele GJ; Jaspars LH; Willemze R; Meijer CJ
J Clin Pathol; 1999 Feb; 52(2):129-36. PubMed ID: 10396241
[TBL] [Abstract][Full Text] [Related]
13. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
14. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.
Pittaluga S; Wlodarska I; Pulford K; Campo E; Morris SW; Van den Berghe H; De Wolf-Peeters C
Am J Pathol; 1997 Aug; 151(2):343-51. PubMed ID: 9250148
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.
Suzuki R; Kagami Y; Takeuchi K; Kami M; Okamoto M; Ichinohasama R; Mori N; Kojima M; Yoshino T; Yamabe H; Shiota M; Mori S; Ogura M; Hamajima N; Seto M; Suchi T; Morishima Y; Nakamura S
Blood; 2000 Nov; 96(9):2993-3000. PubMed ID: 11049976
[TBL] [Abstract][Full Text] [Related]
16. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
17. Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization.
de Bruin PC; Kummer JA; van der Valk P; van Heerde P; Kluin PM; Willemze R; Ossenkoppele GJ; Radaszkiewicz T; Meijer CJ
Blood; 1994 Dec; 84(11):3785-91. PubMed ID: 7524749
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
[TBL] [Abstract][Full Text] [Related]
19. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance?
Brink AA; Oudejans JJ; van den Brule AJ; Kluin PM; Horstman A; Ossenkoppele GJ; van Heerde P; Jiwa M; Meijer CJ
Mod Pathol; 1998 Apr; 11(4):376-83. PubMed ID: 9578089
[TBL] [Abstract][Full Text] [Related]
20. Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
Bakshi NA; Finn WG; Schnitzer B; Valdez R; Ross CW
Arch Pathol Lab Med; 2007 May; 131(5):742-7. PubMed ID: 17488159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
